Founded by Syncona in partnership with experts in Treg cell therapy, Quell is focused on developing advanced Treg therapies for solid organ transplant and autoimmune conditions. With a vision to become a global biopharmaceutical company, Quell aims to deliver innovative therapies for autoimmune and inflammatory diseases, as well as preventing organ rejection, using modular engineered Tregs.